The Long Journey from Diagnosis to Therapy

Literature Cited

1. 1. 

   Bakker E, Goor N, Wrogemann K, Kunkel LM, Fenton WA et al. 1985. Prenatal diagnosis and carrier detection of Duchenne muscular dystrophy with closely linked RFLPs. Lancet 325:655–58
   [Google Scholar]
2. 2. 

   Botstein D, White RL, Skolnick M, Davis RW 1980. Construction of a genetic linkage map in man using restriction fragment length polymorphisms. Am. J. Hum. Genet. 32:314–31
   [Google Scholar]
3. 3. 

   Cohn RD, Campbell KP. 2000. Molecular basis of muscular dystrophies. Muscle Nerve 23:1456–71
   [Google Scholar]
4. 4. 

   Collins FS, Riordan JR, Tsui LC 1990. The cystic fibrosis gene: isolation and significance. Hosp. Pract. 25:47–57
   [Google Scholar]
5. 5. 

   Crudele JM, Chamberlain JS. 2019. AAV-based gene therapies for the muscular dystrophies. Hum. Mol. Genet. 28:R102–7
   [Google Scholar]
6. 6. 

   Davies KE, Young BD, Elles RG, Hill ME, Williamson R 1981. Cloning of a representative genomic library of the human X chromosome after sorting by flow cytometry. Nature 293:374–76
   [Google Scholar]
7. 7. 

   Demirci S, Leonard A, Haro-Mora JJ, Uchida N, Tisdale JF 2019. CRISPR/Cas9 for sickle cell disease: applications, future possibilities, and challenges. Adv. Exp. Med. Biol. 1144:37–52
   [Google Scholar]
8. 8. 

   Drayna D, Davies KE, Hartley D, Mandel JL, Camerino G et al. 1984. Genetic mapping of the human X chromosome by using restriction fragment length polymorphisms. PNAS 81:2836–39
   [Google Scholar]
9. 9. 

   Duan DS. 2018. Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol. Ther. 26:2337–56
   [Google Scholar]
10. 10. 

    Emery AEH. 2002. The muscular dystrophies. Lancet 359:687–95
    [Google Scholar]
11. 11. 

    England SB, Nicholson LVB, Johnson MA, Forrest SM, Love DR et al. 1990. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343:180–82
    [Google Scholar]
12. 12. 

    Guiraud S, Aartsma-Rus A, Vieira NM, Davies KE, van Ommen G-JB, Kunkel LM 2015. The pathogenesis and therapy of muscular dystrophies. Annu. Rev. Genom. Hum. Genet. 16:281–308
    [Google Scholar]
13. 13. 

    Guiraud S, Roblin D, Kay DE 2018. The potential of utrophin modulators for the treatment of Duchenne muscular dystrophy. Expert Opin. Orphan Drugs 6:179–92
    [Google Scholar]
14. 14. 

    Gusella JF. 1984. Genetic linkage of the Huntington's disease gene to a DNA marker. Can. J. Neurol. Sci. 11:421–25
    [Google Scholar]
15. 15. 

    Kan YW, Dozy AM. 1978. Antenatal diagnosis of sickle-cell anæmia by D.N.A. analysis of amniotic-fluid cells. Lancet 312:910–12
    [Google Scholar]
16. 16. 

    Kingston HM, Harper PS. 1983. Genetic linkage between Becker muscular dystrophy and polymorphic DNA probes on the short arm of the X chromosome. J. Med. Genet. 20:454–58
    [Google Scholar]
17. 17. 

    Lefebvre S, Burglin L, Reboullet S, Clermont O, Burlet P et al. 1995. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80:155–65
    [Google Scholar]
18. 18. 

    Love DR, Hill DF, Dickson G, Spurr NK, Byth BC et al. 1989. An autosomal transcript in skeletal muscle with homology to dystrophin. Nature 339:55–58
    [Google Scholar]
19. 19. 

    Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac L et al. 2016. Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes. Mol. Ther. 24:Suppl. 1S190
    [Google Scholar]
20. 20. 

    Murray JM, Davies KE, Harper PS, Meredith L, Mueller CR, Williamson R 1982. Linkage relationship of a cloned DNA sequence on the short arm of the X chromosome to Duchenne muscular dystrophy. Nature 300:69–71
    [Google Scholar]
21. 21. 

    Talbot K, Tizzano EF. 2017. The clinical landscape for SMA in a new therapeutic era. Gene Ther 24:529–33
    [Google Scholar]
22. 22. 

    Verhaart IEC, Aartsma-Rus A. 2019. Therapeutic developments for Duchenne muscular dystrophy. Nat. Rev. Neurol. 15:373–86
    [Google Scholar]
23. 23. 

    Wilkinson IVL, Perkins KJ, Dugdale H, Moir L, Vuorinen A et al. 2020. Chemical proteomics and phenotypic profiling identifies the aryl hydrocarbon receptor as a molecular target of the utrophin modulator ezutromid. Angew. Chem. Int. Ed. 59:2420–28
    [Google Scholar]
24. 24. 

    Willard HF, Schmeckpeper BJ, Smith KD, Goss SJ 1982. Regional localization of an X-specific DNA restriction fragment on the human X chromosome. Cytogenet. Cell Genet. 32:328 Abstr
    [Google Scholar]